The approval was based on data from 3 phase 3 trials which compared the efficacy of different dosing regimens of ...

Targeted prevention strategies and increased public awareness and vaccination coverage are needed to reduce the significant ...

More rapid and targeted microbial treatment for patients with community-acquired pneumonia occurred via routine use of polymerase chain reaction testing for lower respiratory tract pathogens.

A regulatory decision is expected in the fourth quarter of 2024. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for tapinarof cream, 1% for the ...

Findings suggest the need to reconsider American Society of Anesthesiologists 2023 guidelines recommending that glucagon-like peptide 1 receptor agonists be withheld from patients preoperatively.

In patients with COVID-19 with acute respiratory failure, probability of 1-year survival was 84.42% in those who used antifibrotics vs 69.87% in those who did not. The use of antifibrotic agents ...

Protection conferred by the 2023-2024 formulation of the COVID-19 vaccine was modest in the period before JN.1 predominance but was lower thereafter. The 2023-2024 formulation of the mRNA COVID-19 ...

A new diagnostic method for urinary tract infection in pediatric patients older than 2 months blends the liberal approach taken by the American Academy of Pediatrics 2011 guidelines and the ...

Atopic dermatitis is significantly associated with herpes simplex virus keratitis risk. Individuals with atopic conditions, particularly atopic dermatitis with atopic blepharitis, are at an increased ...

Increased protection against COVID-19-related hospitalization was observed among immunocompromised adults who received the updated 2023-2024 COVID-19 vaccine. The updated 2023-2024 COVID-19 vaccine ...

Older patients, those on chronic hemodialysis, and those receiving nitrofurantoin were more likely to experience multiple Clostridioides difficile recurrences and may benefit from the use of early ...

No new safety or tolerability concerns were observed with Biktarvy during pregnancy and postpartum. The Food and Drug Administration (FDA) has approved updated labeling for Biktarvy ® (bictegravir 50 ...